Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012–2023: A US Cohort Study
These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes.
Authors
- Catherine B. Johannes (ORCID: https://orcid.org/0000-0002-0586-9886)
- David Vizcaya (ORCID: https://orcid.org/0000-0003-0248-7636)
- Anam Khan (ORCID: https://orcid.org/0000-0002-7827-6854)
- J. Bradley Layton (ORCID: https://orcid.org/0000-0003-0994-5820)
- Nikolaus G. Oberprieler
- Ryan Ziemiecki (ORCID: https://orcid.org/0000-0002-1774-7034)
- Craig I Coleman (ORCID: https://orcid.org/0000-0003-4868-7158)
- Csaba Pal Kovesdy (ORCID: https://orcid.org/0000-0002-8204-911X)
- Fangfang Liu (ORCID: https://orcid.org/0000-0002-9527-1131)
Institutions
- Hartford Hospital (US)
- University of Connecticut (US)
- University of Tennessee Health Science Center (US)
- RTI Health Solutions (US)
- Hartford Financial Services (United States)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s13300-025-01825-5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00